The Journal of Thoracic and Cardiovascular Surgery
Volume 137, Issue 4 , Pages 824-828 , April 2009

Exogenous surfactant attenuation of ischemia–reperfusion injury in the lung through alteration of inflammatory and apoptotic factors

  • Bart P. van Putte, PhD, MD

      Affiliations

    • Department of Intensive Care Medicine, University Medical Center, Utrecht, The Netherlands
    • Department of Cardiothoracic Surgery, St Antonius Hospital, Nieuwegein, The Netherlands
    • Corresponding Author InformationAddress for reprints: Bart P. van Putte, PhD, MD, Department of Cardiothoracic Surgery, St. Antonius Hospital, Koekoekslaan 1, Nieuwegein, The Netherlands.
    • ,
  • Pieter M. Cobelens, PhD

      Affiliations

    • Department of Intensive Care Medicine, University Medical Center, Utrecht, The Netherlands
    • Laboratory for Psychoneuroimmunology, University Medical Center, Utrecht, The Netherlands
    • ,
  • Niels van der Kaaij, PhD

      Affiliations

    • Department of Anaesthesiology, Erasmus Medical Center, Rotterdam, The Netherlands
    • ,
  • Burkhard Lachmann, PhD, MD

      Affiliations

    • Department of Anaesthesiology, Erasmus Medical Center, Rotterdam, The Netherlands
    • ,
  • Annemieke Kavelaars, PhD

      Affiliations

    • Laboratory for Psychoneuroimmunology, University Medical Center, Utrecht, The Netherlands
    • ,
  • Cobi J. Heijnen, PhD

      Affiliations

    • Laboratory for Psychoneuroimmunology, University Medical Center, Utrecht, The Netherlands
    • ,
  • Jozef Kesecioglu, PhD, MD

      Affiliations

    • Department of Intensive Care Medicine, University Medical Center, Utrecht, The Netherlands

Received 18 February 2008 ,Revised 21 July 2008 ,Accepted 28 August 2008.

References 

  1. van Helden HP, Kuijpers WC, Langerwerf PE, Langen RC, Haagsman HP, Bruijnzeel PL. Efficacy of Curosurf in a rat model of acute respiratory distress syndrome. Eur Respir J. 1998;12:533–539
  2. Chen CM, Fang CL, Chang CH. Surfactant and corticosteroid effects on lung function in a rat model of acute lung injury. Crit Care Med. 2001;29:2169–2175
  3. Verbrugge SJ, Vazquez de Anda G, Gommers D, Neggers SJ, Sorm V, Böhm SH, et al. Exogenous surfactant preserves lung function and reduces alveolar Evans blue dye influx in a rat model of ventilation-induced lung injury. Anesthesiology. 1998;89:467–474
  4. Hausen B, Rohde R, Hewitt CW, Schroeder F, Beuke M, Ramsamooj R, et al. Exogenous surfactant treatment before and after sixteen hours of ischemia in experimental lung transplantation. J Thorac Cardiovasc Surg. 1997;113:1050–1058
  5. Novick RJ, MacDonald J, Veldhuizen RA, Wan F, Duplan J, Denning . L et al. Evaluation of surfactant treatment strategies after prolonged graft storage in lung transplantation. Am J Respir Crit Care Med. 1996;154:98–104
  6. Erasmus ME, Petersen AH, Hofstede G, Haagsman HP, Bambang OS, Prop J. Surfactant treatment before reperfusion improves the immediate function of lung transplants in rats. Am J Respir Crit Care Med. 1996;153:665–670
  7. Wright JR. Immunoregulatory functions of surfactant proteins. Nat Rev Immunol. 2005;5:58–68
  8. Antal JM, Divis LT, Erzurum SC, Wiedemann HP, Thomassen MJ. Surfactant suppresses NF-κ B activation in human monocytic cells. Am J Respir Cell Mol Biol. 1996;14:374–379
  9. Thomassen MJ, Antal JM, Connors MJ, Meeker DP, Wiedemann HP. Characterization of exosurf (surfactant)-mediated suppression of stimulated human alveolar macrophage cytokine responses. Am J Respir Cell Mol Biol. 1994;10:399–404
  10. Baur FM, Brenner B, Goetze-Speer B, Neu S, Speer CP. Natural porcine surfactant (Curosurf) down-regulates mRNA of tumor necrosis factor-alpha (TNF-α) and TNF-α type II receptor in lipopolysaccharide-stimulated monocytes. Pediatr Res. 1998;44:32–36
  11. Vreugdenhil HA, Lachmann B, Haitsma JJ, Zijlstra J, Heijnen CJ, Jansen NJ, et al. Exogenous surfactant restores lung function but not peripheral immunosuppression in ventilated surfactant-deficient rats. Exp Lung Res. 2006;32:1–14
  12. Krause MF, Wiemann T, Reisner A, Orlowska-Volk M, Köhler H, Ankermann T. Surfactant reduces extravascular lung water and invasion of polymorphonuclear leukocytes into the lung in a piglet model of airway lavage. Pulm Pharmacol Ther. 2005;18:129–139
  13. Kinniry P, Pick J, Stephens S, Jain D, Solomides CC, Niven R, et al. KL4-surfactant prevents hyperoxic and LPS-induced lung injury in mice. Pediatr Pulmonol. 2006;41:916–928
  14. van Kaam AH, Lutter R, Lachmann RA, Haitsma JJ, Herting E, Snoek M, et al. Effect of ventilation strategy and surfactant on inflammation in experimental pneumonia. Eur Respir J. 2005;26:112–117
  15. Stamme C, Brasch F, von Bethmann A, Uhlig S. Effect of surfactant on ventilation-induced mediator release in isolated perfused mouse lungs. Pulm Pharmacol Ther. 2002;15:455–461
  16. Rasaiah VP, Malloy JL, Lewis JF, Veldhuizen RA. Early surfactant administration protects against lung dysfunction in a mouse model of ARDS. Am J Physiol Lung Cell Mol Physiol. 2003;284:L783–L790
  17. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003;374:1–20
  18. Farivar AS, Merry HE, Fica-Delgado MJ, McCourtie AS, Mackinnon-Patterson BC, Mulligan MS. Interleukin-6 regulation of direct lung ischemia reperfusion injury. Ann Thorac Surg. 2006;82:472–478
  19. Meng ZH, Dyer K, Billiar TR, Tweardy DJ. Distinct effects of systemic infusion of G-CSF vs. IL-6 on lung and liver inflammation and injury in hemorrhagic shock. Shock. 2000;14:41–48
  20. Dinant S, Vetelainen RL, Florquin S, van Vliet AK, van Gulik TM. IL-10 attenuates hepatic I/R injury and promotes hepatocyte proliferation. J Surg Res. 2007;141:176–182
  21. Hess PJ, Seeger JM, Huber TS, Welborn MB, Martin TD, Harward TR, et al. Exogenously administered interleukin-10 decreases pulmonary neutrophil infiltration in a tumor necrosis factor-dependent murine model of acute visceral ischemia. J Vasc Surg. 1997;26:113–118
  22. Engles RE, Huber TS, Zander DS, Hess PJ, Welborn MB, Moldawer LL, et al. Exogenous human recombinant interleukin-10 attenuates hindlimb ischemia-reperfusion injury. J Surg Res. 1997;69:425–428
  23. Eppinger MJ, Ward PA, Bolling SF, Deeb GM. Regulatory effects of interleukin-10 on lung ischemia-reperfusion injury. J Thorac Cardiovasc Surg. 1996;112:1301–1305
  24. Baron RM, Carvajal IM, Fredenburgh LE, Liu X, Porrata Y, Cullivan ML, et al. Nitric oxide synthase-2 down-regulates surfactant protein-B expression and enhances endotoxin-induced lung injury in mice. FASEB J. 2004;18:1276–1278
  25. Mehta S. The effects of nitric oxide in acute lung injury. Vascul Pharmacol. 2005;43:390–403
  26. Mikawa K, Nishina K, Takao Y, ONO-1714 Obara H. a nitric oxide synthase inhibitor, attenuates endotoxin-induced acute lung injury in rabbits. Anesth Analg. 2003;97:1751–1755
  27. Ng CS, Wan S, Arifi AA, Yim AP. Inflammatory response to pulmonary ischemia-reperfusion injury. Surg Today. 2006;36:205–214
  28. Struber M, Fischer S, Niedermeyer J, Warnecke G, Gohrbandt B, Gorler A, et al. Effects of exogenous surfactant instillation in clinical lung transplantation: a prospective, randomized trial. J Thorac Cardiovasc Surg. 2007;133:1620–1625

PII: S0022-5223(08)01466-9

doi: 10.1016/j.jtcvs.2008.08.046

The Journal of Thoracic and Cardiovascular Surgery
Volume 137, Issue 4 , Pages 824-828 , April 2009

Article Tools

* Image Usage & Resolution